ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2015
Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 50 citations in OpenAlex.
- Article
- Agomelatine decreased cocaine-induced locomotor activity in rats; a dose-time response study.Frontiers in pharmacology · 2026Article
- Brain circadian clocks timing the 24h rhythms of behavior.Npj biological timing and sleep · 2025Review
- Treatment of insomnia associated with alcohol and opioid use: a narrative review.Sleep and biological rhythms · 2024Review
- Disrupted Circadian Rhythms and Substance Use Disorders: A Narrative Review.Clocks & sleep · 2024Review
- Improving behavioral deficits induced by perinatal ethanol and stress exposure in adolescent male rat progeny via maternal melatonin treatment.Psychopharmacology · 2024Article
- Exploring the potential use of melatonin as a modulator of tramadol-induced rewarding effects in rats.Frontiers in pharmacology · 2024Article
- A Complex Relationship Among the Circadian Rhythm, Reward Circuit and Substance Use Disorder (SUD).Psychology research and behavior management · 2024Review
- Neurotransmitters crosstalk and regulation in the reward circuit of subjects with behavioral addiction.Frontiers in psychiatry · 2024Review
- Review
- Melatonin Reduces Alcohol Drinking in Rats with Disrupted Function of the Serotonergic System.Journal of personalized medicine · 2022Article
- Melatonin attenuates morphine-induced conditioned place preference in Wistar rats.Brain and behavior · 2021Article
- Dopamine D1 and D2 receptors are distinctly associated with rest-activity rhythms and drug reward.The Journal of clinical investigation · 2021Article
- Article
- Melatonin Blocks Morphine-Induced Place Preference: Involvement of GLT-1, NF-κB, BDNF, and CREB in the Nucleus Accumbens.Frontiers in behavioral neuroscience · 2021Article
- How Psychoactive Drugs and the Circadian Clock Are Enlightening One Another.Advances in experimental medicine and biology · 2021Article
- Translational approach to understanding momentary factors associated with alcohol consumption.British journal of pharmacology · 2020Review
- Increase of orexin A in the peripheral blood of adolescents with Internet gaming disorder.Journal of behavioral addictions · 2020Article
- Melatonin decreases cocaine-induced locomotor activity in pinealectomized rats.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2020Article
- Drinking Levels and Profiles of Alcohol Addicted Rats Predict Response to Nalmefene.Frontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melatonin is an endogenous synchronizer of biological rhythms and a modulator of physiological functions and behaviors of all mammals. Reduced levels of melatonin and a delay of its nocturnal peak concentration have been found in alcohol-dependent patients and rats. Here we investigated whether the melatonergic system is a novel target to treat alcohol addiction. Male Wistar rats were subjected to long-term voluntary alcohol consumption with repeated abstinence phases. Circadian drinking rhythmicity and patterns were registered with high temporal resolution by a drinkometer system and analyzed by Fourier analysis. We examined potential antirelapse effect of the novel antidepressant drug agomelatine. Given that agomelatine is a potent MT1 and MT2 receptor agonist and a 5-HT2C antagonist we also tested the effects of melatonin itself and the 5-HT2C antagonist SB242084. All drugs reduced relapse-like drinking. Agomelatine and melatonin administered at the end of the light phase led to very similar changes on all measures of the post-abstinence drinking behavior, suggesting that effects of agomelatine on relapse-like behavior are mostly driven by its melatonergic activity. Both drugs caused a clear phase advance in the diurnal drinking pattern when compared with the control vehicle-treated group and a reduced frequency of approaches to alcohol bottles. Melatonin given at the onset of the light phase had no effect on the circadian phase and very small effects on alcohol consumption. We conclude that targeting the melatonergic system in alcohol-dependent individuals can induce a circadian phase advance, which may restore normal sleep architecture and reduce relapse behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.